CoreFirst Bank & Trust’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$174K Hold
4,723
0.09% 124
2025
Q4
$240K Hold
4,723
0.13% 109
2025
Q3
$262K Sell
4,723
-62
-1% -$3.63K 0.14% 104
2025
Q2
$330K Hold
4,785
0.19% 94
2025
Q1
$332K Hold
4,785
0.21% 90
2024
Q4
$412K Sell
4,785
-41
-0.8% -$4.43K 0.24% 79
2024
Q3
$575K Hold
4,826
0.33% 66
2024
Q2
$689K Hold
4,826
0.46% 56
2024
Q1
$620K Sell
4,826
-530
-10% -$63.1K 0.39% 63
2023
Q4
$554K Hold
5,356
0.37% 66
2023
Q3
$487K Buy
5,356
+62
+1% +$5.46K 0.35% 71
2023
Q2
$428K Hold
5,294
0.3% 80
2023
Q1
$421K Hold
5,294
0.31% 78
2022
Q4
$358K Hold
5,294
0.27% 90
2022
Q3
$264K Sell
5,294
-98
-2% -$5.25K 0.23% 97
2022
Q2
$300K Sell
5,392
-660
-11% -$36.6K 0.24% 95
2022
Q1
$336K Sell
6,052
-168
-3% -$8.62K 0.23% 96
2021
Q4
$348K Sell
6,220
-20
-0.3% -$1.08K 0.23% 98
2021
Q3
$300K Sell
6,240
-124
-2% -$6K 0.21% 107
2021
Q2
$266K Hold
6,364
0.18% 116
2021
Q1
$215K Sell
6,364
-160
-2% -$5.7K 0.15% 129
2020
Q4
$228K Buy
+6,524
New +$225K 0.17% 113

Other funds holding NVO

CoreFirst Bank & Trust's NVO Position: Q1 2026 in Review

CoreFirst Bank & Trust held its Novo Nordisk (NVO) position steady in Q1 2026 at 4,723 shares worth $174K. The position accounts for 0.09% of the portfolio, ranked #124.

CoreFirst Bank & Trust first reported a position in NVO in Q4 2020 and has held it in 22 quarters since. The position peaked at $689K in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • CoreFirst Bank & Trust held 4,723 shares of Novo Nordisk worth $174K as of Q1 2026.
  • CoreFirst Bank & Trust left its Novo Nordisk share count unchanged in Q1 2026.
  • Novo Nordisk made up 0.09% of CoreFirst Bank & Trust's portfolio in Q1 2026, its #124 holding.
  • CoreFirst Bank & Trust first reported a position in Novo Nordisk in Q4 2020 and has held it in 22 quarters since.
  • CoreFirst Bank & Trust's Novo Nordisk position peaked at $689K in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on CoreFirst Bank & Trust's 13F filing for Q1 2026, filed 3 Jun 2026.